GM-CSF

GM-CSF

GM-CSF Overview

Molecule Name
Macrophage colony stimulating factor 2
Synonyms
GM-CSF,CSF2,MGC131935
Drug Development Progress
Drugs in Clinical Trials9
Approved Drugs0
Highest Development StageNDA/BLA
Target Synonym
GM-CSF,Molgramostin,CSF2,Colony Stimulating Factor 2,Sargramostim,GMCSF,CSF,Granulocyte Macrophage-Colony Stimulating Factor,Granulocyte-Macrophage Colony Stimulating Factor,Colony-Stimulating Factor,Granulocyte-Macrophage Colony-Stimulating Factor,Colony Stimulating Factor 2 (Granulocyte-Macrophage),Molgramostim
Background
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

GM-CSF Product List

Species
  • Human(5)
  • Mouse(1)
Tag
  • Tag Free(5)
  • His Tag & Avi Tag(1)
Host
  • HEK293(6)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(2)
Grade
  • RUO(4)
  • GMP(1)
  • PG (pre-GMP)(1)
Low Endotoxin
  • No(6)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
GM-CSF
Human GM-CSF Protein, premium grade
Human
HEK293
MALSSDS-PAGE
ELISABLICELL BASE

$235.00

20ug
GM-CSF
Mouse GM-CSF Protein, Tag Free
Mouse
HEK293
SDS-PAGE
ELISA

$165.00

20ug
GM-CSF
GMP Human GM-CSF Protein
Human
HEK293
SDS-PAGE
CELL BASE

$510.00

50ug
GM-CSF
Human GM-CSF Protein, Research Grade
Human
HEK293
MALSSDS-PAGE
ELISACELL BASE

$199.00

20ug
GM-CSF
Biotinylated Human GM-CSF Protein, epitope tag free, ultra sensitivity (primary amine labeling)
Human
HEK293
SDS-PAGE
ELISABLI

$300.00

25ug
GM-CSF
Avitag
GMF-H82E3
Biotinylated Human GM-CSF Protein, His,Avitag™ (HPLC verified)
Human
HEK293
HPLCSDS-PAGE
ELISABLI

$300.00

25ug
You Have Viewed 1-6 Of 6 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
OtilimabMOR-04357; GSK-3196165; GSK-165; MOR-103Phase 3 ClinicalUniversity Of Melbourne
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Osteoarthritis; Severe Acute Respiratory Syndrome; Spondylarthritis; Stomach Neoplasms
Details
PlonmarlimabTJM-2; TJ-003234; TJ-003234RAR101Phase 3 ClinicalI-Mab Biopharma Co Ltd
Arthritis, Gouty; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome
Details
Gemogenovatucel-TIND-14205Phase 3 ClinicalGradalis Inc
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma, Ewing; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
PBI-1402PBI-1402Phase 2 ClinicalPrometic Life Sciences
Anemia
Details
Pexastimogene devacirepvecTG-6006; JX-594Phase 2 ClinicalNational Cancer Institute, Regeneron Pharmaceuticals Inc, Samsung Medical Center & Samsung Electronics Devices Llc, Sillajen Inc
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Wilms Tumor
Details
Breast cancer therapy (BriaCell Therapeutics)Phase 2 ClinicalBriacell Therapeutics Corp
Breast Neoplasms; Metastatic breast cancer
Details
GimsilumabMORAb-022; KIN-1901Phase 2 ClinicalMorphotek Inc
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Inflammation; Rheumatic Diseases
Details
MEDI-5395MEDI-5395; MEDI5395Phase 1 ClinicalMedimmune
Solid tumours
Details
BBM-C101Phase 1 ClinicalBelief BioMed Inc
Squamous Intraepithelial Lesions of the Cervix
Details
Customer Reviews